[Federal Register Volume 87, Number 12 (Wednesday, January 19, 2022)]
[Notices]
[Pages 2767-2768]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00887]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY:  Under Secretary of Defense for Personnel and Readiness, 
Department of Defense (DoD).

ACTION:  Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY:  The DoD is publishing this notice to announce that the 
following Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (UFBAP) will take place.

DATES:  Open to the public on day 1 of the meeting Tuesday, January 25, 
2022, 10:00 a.m.-6:00 p.m. and on Day 2 of the meeting January 26, 
2022, 9:00 a.m.-6:00 p.m. (Eastern Standard Time).

ADDRESSES:  The meeting will be held telephonically or via conference 
call. The phone number for the remote access on January 25-26, 2022 is: 
CONUS: 1-888-946-3815; OCONUS: 1-415-228-4881; PARTICIPANT CODE: 
6978956.
    These numbers and the dial-in instructions will also be posted on 
the Uniform Formulary Beneficiary Advisory Panel website at: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel.

FOR FURTHER INFORMATION CONTACT:  Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), <a href="/cdn-cgi/l/email-protection#bedad6df90d0ddcc90d4938890d3dcc690dcdfceccdbcfcbdbcdcacdfed3dfd7d290d3d7d2"><span class="__cf_email__" data-cfemail="86e2eee7a8e8e5f4a8ecabb0a8ebe4fea8e4e7f6f4e3f7f3e3f5f2f5c6ebe7efeaa8ebefea">[email protected]</span></a> (Email). Mailing 
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 
22042-5101. Website: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel. 
The most up-to-date changes to the meeting agenda can be found on the 
website.

SUPPLEMENTARY INFORMATION:  Due to circumstances beyond the control of 
the Department of Defense and the Designated Federal Officer, the UFBAP 
was unable to provide public notification required by 41 CFR 102-
3.150(a) concerning its January 25 through 26, 2022 meeting. 
Accordingly, the Advisory Committee Management Officer for the 
Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-
calendar day notification requirement. This meeting is being held under 
the provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C., 
Appendix) and 41 CFR 102-3.140 and 102-3.150. The Panel will review and 
comment on recommendations made to the Director, Defense Health Agency, 
by the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
    Purpose of the Meeting: The DoD is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

Agenda Items

1. Day 1--January 25, 2022

a. 10:00 a.m.-10:10 a.m. Sign In for UFBAP members
b. 10:10 a.m.-10:20 a.m. Welcome and Opening Remarks by Col Paul J. 
Hoerner, Designated Federal Officer (DFO), UFBAP
c. 10:20 a.m.-10:30 a.m. Introduction of UFBAP Members by Col Hoerner
d. 10:30 a.m.-10:45 a.m. Opening Remarks by UFBAP Co-Chair Senior Chief 
Petty Officer (Ret) Jon R. Ostrowski, Non-Commissioned Officers 
Association
e. 10:45 a.m.-11:00 a.m. Introductory Remarks by CDR Scott Raisor, 
Interim Chief, Formulary Management Branch

2. Discussion of the February 2021 DoD P&T Committee Recommendations

Scheduled Therapeutic Class Reviews
a. 11:00 a.m.-11:30 a.m. Breast Cancer Agents: Cyclin Dependent Kinase 
Inhibitors (LCDR Todd Hansen)
b. 11:30 a.m.-12:00 p.m. Pulmonary III Agents (Dr. Angela Allerman)
c. 12:00 p.m.-1:00 p.m. Break for Lunch
d. 1:00 p.m.-1:45 p.m. Newly Approved Drugs Review (Dr. Amy Lugo, and 
other FMB staff, including CDR Raisor, and MAJ Adam Davies)
e. 1:45 p.m.-2:45 p.m. Pertinent Utilization Management Issues (MAJ 
Davies, and other FMB staff, including Dr. Allerman, and CDR Raisor)
    * Note that the UFBAP Discussion and Vote will follow each section
f. 2:45 p.m.-3:00 p.m. Break

[[Page 2768]]

3. Discussion of the May 2021 DoD P&T Committee Recommendations

Scheduled Therapeutic Class Reviews
a. 3:00 p.m.-3:30 p.m. Menopausal Hormone Therapy: Single Agents, 
Combination Agents, and Vaginal Agents (LCDR Elizabeth Hall)
b. 3:30 p.m.-4:00 p.m. Sleep Disorders: Insomnia (Dr. Lugo)
c. 4:00 p.m.-4:45 p.m. Newly Approved Drugs Review (Dr. Lugo, and other 
FMB staff including, LCDR Hall, MAJ Davies, LCDR Hansen, and Dr. 
Allerman)
d. 4:45 p.m.-5:15 p.m. Pertinent Utilization Management Issues (MAJ 
Davies and other FMB staff including Dr. Allerman, Dr. Lugo, and LCDR 
Hall)
e. 5:15 p.m.-5:30 p.m. Re-evaluation of Nonformulary generics (Dr. 
Allerman)
    * Note that the UFBAP Discussion and Vote will follow each section
f. 5:30 p.m.-5:45 p.m. Closing Remarks by Senior Chief Petty Officer 
(Ret) Ostrowski
g. 5:45 p.m.-6:00 p.m. Closing Remarks by Col Hoerner

Agenda Items

1. Day 2--January 26, 2022

a. 9:00 a.m.-9:10 a.m. Sign In for UFBAP members
b. 9:10 a.m.-9:15 a.m. Welcome and Opening Remarks by Col Hoerner
c. 9:15 a.m.-9:30 a.m. Opening Remarks by Senior Chief Petty Officer 
(Ret) Ostrowski

2. Discussion of the August 2021 DoD P&T Committee Recommendations

Scheduled Therapeutic Class Reviews
a. 9:30 a.m.-10:00 a.m. Leukemia and Lymphoma Agents, Burton Tyrosine 
Kinase Inhibitors LCDR Hansen)
b. 10:00 a.m.-10:30 a.m. Laxative-Cathartics-Stool Softeners--Bowel 
Preparations (Dr. Lugo)
c. 10:30 a.m.-10:45 a.m. Break
d. 10:45 a.m.-11:45 a.m. Newly Approved Drugs Review (Dr. Lugo and 
other FMB staff, including LCDR Hall, LCDR Hansen, Dr. Allerman, CDR 
Raisor, and MAJ Davies)
e. 11:45 a.m.-12:45 p.m. Pertinent Utilization Management Issues (MAJ 
Davies and other FMB staff, including Dr. Lugo, and CDR Raisor)
f. 12:45 p.m.-1:00 p.m. Tier Co-Payment Change for the Pulmonary III 
Agents (CDR Raisor)
g. 1:00 p.m.-1:15 p.m. Brand over Generic Authorization and Tier 1 Co-
Payment Change for the Pulmonary Arterial Hypertension Drugs (Dr. 
Allerman)
    * Note that the UFBAP Discussion and Vote will follow each section
h. 1:15 p.m.-2:15 p.m. Break for Lunch

3. Discussion of the November 2021 DoD P&T Committee Recommendations

Scheduled Therapeutic Class Reviews
a. 2:15 p.m.-3:00 p.m. Continuous Glucose Monitoring Systems--
Therapeutic Agents (Dr. Lugo)
b. 3:00 p.m.-3:30 p.m. Immunological Agents Miscellaneous--Subcutaneous 
Immunoglobulins (LCDR Hansen)
c. 3:30 p.m.-4:30 p.m. Newly Approved Drugs Review (Dr. Lugo and other 
FMB staff including LCDR Hansen, LCDR Giao Phung, LCDR Hall, MAJ Davies 
and Maj Angelina Escano)
d. 4:30 p.m.-4:45 p.m. Break
e. 4:45 p.m.-5:45 p.m. Pertinent Utilization Management Issues (MAJ 
Davies)
    *Note that the UFBAP Discussion and Vote will follow each section
f. 5:45 p.m.-5:55 p.m. Closing Remarks by Senior Chief Petty Officer 
(Ret) Ostrowski
g. 5:55 p.m.-6:00 p.m. Closing Remarks by Col Hoerner

    Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and 
41 CFR 102-3.140 through 102-3.165, and subject to the availability of 
phone lines, this meeting is open to the public. Telephone lines are 
limited and available to the first 220 people dialing in. There will be 
220 line total: 200 domestic and 20 international, including leader 
lines.
    Written Statements: Pursuant to 41 CFR 102-3.10, and section 
10(a)(3) of FACA, interested persons or organizations may submit 
written statements to the Uniform Formulary Beneficiary Advisory Panel 
about its mission and/or the agenda to be addressed in this public 
meeting. Written statements should be submitted to the Uniform 
Formulary Beneficiary Advisory Panel's Designated Federal Officer 
(DFO). The DFO's contact information can be found in the FOR FURTHER 
INFORMATION CONTACT section of this notice. Written comments or 
statements must be received by the Uniform Formulary Beneficiary 
Advisory Panel's DFO at least two (2) calendar days prior to the 
meeting so they may be made available to the Uniform Formulary 
Beneficiary Advisory Panel for its consideration prior to the meeting. 
The DFO will review all submitted written statements and provide copies 
to all Uniform Formulary Beneficiary Advisory Panel members.

    Dated: January 12, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register, Liaison Officer, Department of Defense.
[FR Doc. 2022-00887 Filed 1-18-22; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>